Clinical Trials for Wet Age-Related Macular Degeneration

Wet age-related macular degeneration (wet AMD) is a serious eye condition in which abnormal blood vessels grow beneath the retina and leak fluid or blood, damaging the central vision area. It is the leading cause of severe vision loss in people over 60 in the United States, according to the National Eye Institute.

Treatment with anti-VEGF medications -- injected into the eye by a retinal specialist -- has transformed the ability to slow vision loss in wet AMD. But these treatments require frequent injections, and insurance coverage denials create real barriers to accessing them. Clinical trials are working to improve treatment -- including longer-lasting options, gene therapies, and combination approaches.

What Types of Trials Are Available?

Anti-VEGF trials are studying newer agents and higher-dose formulations that may require fewer injections -- a meaningful benefit for people who find monthly or every-two-month visit schedules burdensome. Gene therapy trials represent one of the most exciting frontiers in wet AMD research. Rather than requiring repeated injections, gene therapy aims to enable retinal cells to produce their own VEGF-blocking proteins continuously. Early-phase trials have shown promising results. Combination therapy trials are studying whether anti-VEGF therapy combined with agents targeting other pathways (like the complement system) can improve outcomes beyond what anti-VEGF alone achieves. Treat-and-extend vs. fixed dosing trials are comparing different injection scheduling strategies to determine the best approach for preserving vision with fewer visits.

Search ClinicalTrials.gov for currently recruiting trials.

Am I Eligible?

Common eligibility factors for wet AMD trials include:

- Active wet AMD confirmed by optical coherence tomography (OCT) or fluorescein angiography

- Prior treatment history (some trials enroll treatment-naive participants; others require prior anti-VEGF experience)

- Visual acuity within a specific range (many trials have minimum and maximum vision thresholds)

- No other significant ocular conditions affecting the study eye

- Age requirements (most wet AMD trials enroll adults 50 and older)

Your retinal specialist is the right guide for evaluating whether a specific trial is appropriate for your current disease status. Talk to your doctor before making any decisions about your treatment.

What If My Insurance Denied My Medication?

Anti-VEGF injections for wet AMD -- including aflibercept (Eylea), bevacizumab (Avastin, often used off-label), ranibizumab (Lucentis), and faricimab (Vabysmo) -- are frequently subject to prior authorization, step therapy requirements, and formulary restrictions. Delays in treatment for wet AMD can have significant consequences for vision.

If your retinal specialist has recommended a specific anti-VEGF agent and your insurer has denied it, you can appeal. Documenting the urgency and medical necessity in a strong prior authorization request or appeal letter is critical.

Simultaneously, clinical trials studying newer anti-VEGF agents or gene therapy may offer access to treatment -- sometimes with less frequent dosing than currently approved options.

Ellen can help you figure out your next step. Start with Ellen →

Frequently Asked Questions

Are clinical trials for wet age-related macular degeneration free?

In most cases, yes. Trial sponsors (pharmaceutical companies, universities, or the NIH) cover the cost of the experimental treatment. You may still have costs for routine care — like doctor visits or standard tests — depending on your insurance. Always ask the trial coordinator what costs you might be responsible for before enrolling.

How do I find wet age-related macular degeneration trials near me?

The best place to start is ClinicalTrials.gov, the official registry of all trials in the US. Search by condition name and filter by your location. Your specialist can also help identify trials at academic medical centers in your region.

Can I join a trial after being denied Eylea or Vabysmo?

Yes, and in many cases a denial can actually make you a stronger candidate — trials often enroll patients who have not responded to or cannot access standard treatments. Talk to your doctor about whether your denial history makes you eligible for open trials studying Eylea or Vabysmo or similar medications.